Dr Helena Earl
Honorary Consultant Medical Oncologist

Dr Helena Earl was appointed to the University of Cambridge, as clinical lecturer and Consultant in Medical Oncology in 1996. She was promoted to Reader in Clinical Cancer Medicine at the University in 2007 for her work in clinical and translational research in breast cancer. This includes leadership roles (Chief Investigator-CI) on the following multi-centre NCRN clinical trials: NEAT adjuvant (Co-CI), Neo-TANGO neoadjuvant (CI), PERSEPHONE adjuvant (CI), and ARTemis neoadjuvant (Co-CI). Translational Cambridge studies in collaboration include NEAT-Science, TANGO-Science, Trans-PERSEPHONE, and Neo-TANGO-Science. Local clinical/translational studies within the Cambridge Breast Research Unit include: MONET – neoadjuvant endocrine therapy (CI); TRANS-Neo. She is also an active trial management group member for the following adjuvant breast cancer trials: ABC, aTTom, TACT, tAnGo, OPTIMA and ROSCO. Dr Earl has collaborative research links with the Universities of Birmingham, Warwick, and Edinburgh in the UK, and Internationally with the Institut National du Cancer (INCa) in France, and with the University of Modena (Italy).

Current grant income for clinical and translational research in collaboration is over £10.6m. She has published 125 peer-reviewed original papers and 190 abstracts from National and International meetings. She has also contributed 22 book chapters, book reviews and articles for patients. Ten research papers are detailed below:

  1. Alaa Ali*, Elena Provenzano*, John M.S. Bartlett, Jean Abraham, Kristy Driver, Alison F. Munro, Christopher Twelves, Christopher J. Poole, Louise Hiller, Janet Dunn, Helena M. Earl, Carlos Caldas, Paul Pharoah. Prognosis of early breast cancer by immunohistochemistry-defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. Int J Cancer. 2013 Mar 9. doi: 10.1002/ijc.28150 [Epub ahead of print].
  2. Provenzano E, Vallier A-L, Walland K, Champ R, Bowden S, Grier A, Fenwick N, Abraham J, Iddawela M, Caldas C, Hiller L, Dunn J, and Earl HM.A Central Review of Histopathology Reports after Breast Cancer Neoadjuvant Chemotherapy in the Neo-tAnGo Trial. Br J Cancer 2013 Mar 5;108(4):866-72.
  3. Earl HM, Hiller L, Dunn JA, Vallier A-L, Jordan S, Bathers S, Bowden S, Bardwell H, Grieve R, Spooner DA, Agrawal R, Fernando I, Brunt AM, O’Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RCF, Twelves CJ, Bartlett J, Pharoah P, Caldas C, and Poole CJ for the NEAT Investigators and the SCTBG.  Seven year follow-up of Epirubicin followed by CMF in adjuvant early breast cancer: Definitive results of the randomised phase III National Epirubicin Adjuvant Trial (NEAT) and Scottish Cancer Trials Breast Group BR9601 trial. Br J Cancer 2012 Oct 9;107(8):1257-1267.
  4. Jean E Abraham, Mel J Maranian, Kristy E Driver, Helena M Earl, Alison M Dunning, Paul D.P. Pharoah, Carlos Caldas.  CYP2D6 gene variants and their association with breast cancer susceptibility.  Cancer Epidemiol Biomarkers Prev. 2011 Apr 28. [Epub ahead of print]
  5. Gounaris I, Britton P , Taylor K, Wallis M, Hiller L, Vallier A-L, Provenzano E, Iddawela M, Earl H, Sinnatamby R. Accuracy of uni-dimensional and volumetric measurements in predicting good pathological response to neoadjuvant chemotherapy in breast cancer patients.  Breast Cancer Res Treat. 2011 Jun;127(2):459-69.
  6. Andrew Tutt, Mark Robson, Judy E Garber, Susan Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita Schmutzler, Andrew Wardley, Gillian Mitchell, Helena Earl, Mark Wickens, James Carmichael.  Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.  Lancet 2010; 376: 235-44.
  7. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg D, Earl HM, Dunning AM, Pharoah PDP, Caldas C.  CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.  Breast Cancer Research 2010 Aug 23;12(4):R64.
  8. J.M.S. Bartlett, A Munro, J.A. Dunn, S. Jordan, C McConkey, C.J. Twelves, D.A. Cameron, J. Thomas, F Campbell, D.W.Rea, E. Provenzano, P Pharoah, L.Hiller, C. Caldas, H. Earl and C.J. Poole.  Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).  Lancet Oncol. 2010 Mar;11(3):266-74.
  9. P Ellis, P Barrett-Lee, L. Johnson, A. Wardley, S O’Reilly, M Verrill, I Smith, J Yarnold, R Coleman, H Earl, D Bloomfield, D Cameron, P Hopwood, S Johnston, M Dowsett, J Bartlett, I Ellis, C Peckitt, J Banerji, E Hall & JM Bliss for the TACT Trial Management Group; TACT Trialists.  Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009 May16; 373(9676):1681-92.
  10. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve R, Spooner D, Agrawal RK, Fernando IN, Brunt AM, O’Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL,  Stanley A, Harvey P, McAdam K, Foster L, Leonard RCF, Twelves CJ, for the NEAT Investigators and the SCTBG.  Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. N Engl J Med, 2006; 355 : 1851-62